Significant biosimilar activities this week include
11 May 20 |
it had recovered the global rights to brazikumab
from Amgen. AstraZeneca had previously collaborated with Amgen to jointly develop and commercialise the product. Brazikumab is a monoclonal antibody targeting IL-23 and is currently in Ph II and Ph III trials for the treatment of ulcerative colitis and Crohn’s disease. The American Journal of Managed Care reported
the development, noting the role the AbbVie-Allergan merger and the FTC played in facilitating the deal. The FTC ruled that as both AbbVie and Allergen were developing IL-23 inhibitors, there would not be a sufficiently competitive environment for these products unless brazikumab was released from Amgen/Allergan.
18 May 20 |
Samsung Bioepis announced 24-week interim results
from a Ph III trial of SB11 (a proposed ranibizumab
biosimilar) in patients with neovascular age-related macular degeneration. Samsung Bioepis announced that the primary endpoints of the trial were met, suggesting that SB11 will be a valuable treatment option for nAMD.
18 May 20 |
JHL Biotech announced
that the first group of subjects in the Australian randomised Ph I trials of JHL1266 (proposed denosumab
) were dosed.
19 May 20 |
Korea Biomedical Review announced
that Daewon Pharmaceutical has launched Terrosa® (teriparatide
) in South Korea. Terrosa® was developed by Gedeon Richter and is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture, and osteoporosis associated with sustained systemic glucocorticoid therapy in men and women at increased risk for fracture.
22 May 20 |
JD Supra reported
on Mylan’s Q1 earnings call.
In the call, Mylan announced its partner Biocon had received FDA pre-approval of its Malaysian manufacturing facility, as well as announcing a planned launch for Nepexto® (etanercept) in Europe within months. The BLA and marketing authorisation for its bevacizumab
candidate is currently under review by the FDA and European authorities. Mylan also confirmed that its biosimilar insulin
projects remain on target.
22 May 20 |
Fresenius Kabi announced
that the EMA has accepted its marketing application for MSB11455, a proposed pegfilgrastim